Effect of mesenchymal stem cell conditioned medium on hepatocyte matrix implant to alleviate liver cirrhosis in rats.

IF 3 4区医学 Q4 CELL & TISSUE ENGINEERING

Regenerative medicine Pub Date : 2025-10-01 Epub Date: 2025-10-14 DOI:10.1080/17460751.2025.2574178

Siufui Hendrawan, Jennifer Lheman, Fitriya Nur Annisa Dewi, Nuraeni, Permanawati, Hans Ulrich Baer

{"title":"Effect of mesenchymal stem cell conditioned medium on hepatocyte matrix implant to alleviate liver cirrhosis in rats.","authors":"Siufui Hendrawan, Jennifer Lheman, Fitriya Nur Annisa Dewi, Nuraeni, Permanawati, Hans Ulrich Baer","doi":"10.1080/17460751.2025.2574178","DOIUrl":null,"url":null,"abstract":"Background: Hepatocyte transplantation has gained importance as an alternative treatment to orthotopic liver transplantation for end-stage liver disease. This study explores the modification of the hepatocyte matrix implant (HMI) procedure by replacing islet cells with conditioned medium (CM) derived from human umbilical cord-MSC (hUC-MSC) supplementation to alleviate liver cirrhosis in a rat model.Methods: The male Sprague Dawley rats were induced liver cirrhosis using thioacetamide for 11 weeks, and implanted with matrices on the small bowel mesentery, according to the groups. Four groups were assessed: blank matrix (cell-free), hepatocytes seeded-matrix (Hep), hepatocytes+islets co-seeded-matrix (Hep:Islet), and hepatocytes seeded-matrix supplemented with CM (Hep+CM).Results: In vitro, the Hep+CM group showed significantly higher hepatocyte proliferation than the Hep:Islet group, though albumin production was similar. The in vivo study further confirmed that the implanted hepatocytes remained viable and were able to produce albumin for at least 4 months post-implantation. Liver function parameters were shown to be improved in Hep:Islet and Hep+CM groups. Notably, collagen deposition in the liver was lower in Hep:Islet and Hep+CM groups compared to other groups.Conclusion: These findings suggest that CM can effectively replace islet in supporting hepatocyte proliferation and function, enhancing the therapeutic potential of HMI procedure. No writing assistance was utilized in the production of this manuscript or liver cirrhosis treatment.","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"475-487"},"PeriodicalIF":3.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12562743/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Regenerative medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1080/17460751.2025.2574178","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatocyte transplantation has gained importance as an alternative treatment to orthotopic liver transplantation for end-stage liver disease. This study explores the modification of the hepatocyte matrix implant (HMI) procedure by replacing islet cells with conditioned medium (CM) derived from human umbilical cord-MSC (hUC-MSC) supplementation to alleviate liver cirrhosis in a rat model.

Methods: The male Sprague Dawley rats were induced liver cirrhosis using thioacetamide for 11 weeks, and implanted with matrices on the small bowel mesentery, according to the groups. Four groups were assessed: blank matrix (cell-free), hepatocytes seeded-matrix (Hep), hepatocytes+islets co-seeded-matrix (Hep:Islet), and hepatocytes seeded-matrix supplemented with CM (Hep+CM).

Results: In vitro, the Hep+CM group showed significantly higher hepatocyte proliferation than the Hep:Islet group, though albumin production was similar. The in vivo study further confirmed that the implanted hepatocytes remained viable and were able to produce albumin for at least 4 months post-implantation. Liver function parameters were shown to be improved in Hep:Islet and Hep+CM groups. Notably, collagen deposition in the liver was lower in Hep:Islet and Hep+CM groups compared to other groups.

Conclusion: These findings suggest that CM can effectively replace islet in supporting hepatocyte proliferation and function, enhancing the therapeutic potential of HMI procedure. No writing assistance was utilized in the production of this manuscript or liver cirrhosis treatment.

查看原文本刊更多论文

间充质干细胞条件培养基对肝细胞基质移植缓解大鼠肝硬化的影响。

背景：肝细胞移植作为一种替代原位肝移植治疗终末期肝病的重要方法。本研究探讨了肝细胞基质植入（HMI）过程的改进，用人脐带间充质干细胞（hUC-MSC）补充的条件培养基（CM）代替胰岛细胞，以减轻大鼠模型中的肝硬化。方法：采用硫乙酰胺诱导雄性sd大鼠肝硬化11周，并按组分在小肠肠系膜上植入基质。评估四组：空白基质（无细胞）、肝细胞种子基质（Hep）、肝细胞+胰岛共种子基质（Hep：胰岛）和肝细胞种子基质中添加CM （Hep+CM）。结果：在体外，Hep+CM组的肝细胞增殖明显高于Hep：胰岛组，但白蛋白的产生与Hep：胰岛组相似。体内研究进一步证实，植入的肝细胞在植入后至少4个月内保持活力并能够产生白蛋白。肝：胰岛组和肝+CM组肝功能指标均有改善。值得注意的是，与其他组相比，Hep：胰岛组和Hep+CM组肝脏中的胶原沉积较低。结论：CM可有效替代胰岛支持肝细胞增殖和功能，增强HMI手术的治疗潜力。在本手稿的制作和肝硬化治疗中没有使用任何写作辅助。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.